In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28 days
- PMID: 31525767
- DOI: 10.7326/ACPJ201909170-033
In treatment-resistant depression, adding esketamine nasal spray to an oral antidepressant improved symptoms at 28 days
Comment on
-
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. Am J Psychiatry. 2019. PMID: 31109201 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical